Search results
Results from the WOW.Com Content Network
About Editas Medicine As a clinical-stage gene editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and ...
Editas Medicine was originally founded with the name "Gengine, Inc." in September 2013 by Feng Zhang of the Broad Institute, Jennifer Doudna of the University of California, Berkeley, [7] and George Church, David Liu, and J. Keith Joung of Harvard University, with funding from Third Rock Ventures, Polaris Partners and Flagship Ventures; the name was changed to the current "Editas Medicine" two ...
The $1,000 genome refers to an era of predictive and personalized medicine during which the cost of fully sequencing an individual's genome is roughly one thousand USD. [ 1 ] [ 2 ] It is also the title of a book by British science writer and founding editor of Nature Genetics , Kevin Davies. [ 3 ]
genXtraits is an innovative start-up based in the San Francisco Bay Area, which has developed proprietary algorithms that identify specific repressor sequences in genomes that can be modified, via targeted gene editing, to activate genes which produce valuable traits such as environmental stress tolerance and improved nutritional composition.
Gene editing is the process by which specific changes are made to the sequence of a gene within the context of a host cell. By editing the code of a patient-derived cell to introduce or repair a genetic change believed to drive disease, a patient’s disease can be reproduced in a laboratory setting, letting researchers ask important biological questions of potential drugs or cell therapies ...
For more companies, take a look at 5 Most Promising Gene Therapy Companies to Watch. Gene therapy is a revolutionary new technology that has followed the growing advances in computing power. The ...
For premium support please call: 800-290-4726 more ways to reach us
Precision BioSciences' proprietary technology is the ARCUS platform and ARCUS nucleases. [4] [8] ARCUS nucleases are based on a naturally occurring genome editing enzyme, I-CreI, a homing endonuclease that evolved in the algae Chlamydomonas reinhardtii [4] [12] to make highly specific cuts and DNA insertions in cellular DNA. [15]